<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Cancer Sciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/38E7D9DC-E2D5-40BF-8575-9301AB44C0DE"><gtr:id>38E7D9DC-E2D5-40BF-8575-9301AB44C0DE</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>D</gtr:otherNames><gtr:surname>Hislop</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B863A1B5-18E2-4DCE-8A84-7DD2C73D6597"><gtr:id>B863A1B5-18E2-4DCE-8A84-7DD2C73D6597</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Blackbourn</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800154"><gtr:id>B1EC5357-F98B-4420-B9E1-6D5520288191</gtr:id><gtr:title>Understanding the inhibition of antigen-specific T cells by the KSHV protein vOX2 and its cellular counterpart, CD200</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800154</gtr:grantReference><gtr:abstractText>Kaposi?s sarcoma-associated herpesvirus (KSHV) is the probable cause of Kaposi?s sarcoma (KS), a cancer affecting AIDS patients and the most prevalent tumour in Africa. KSHV interferes with the immune response, which normally helps to prevent viral diseases. This interference presumably helps the virus to become established in the infected person, leading to disease. Our work suggests that one KSHV protein, called vOX2, is responsible for this immune interference since it suppresses the immune response: it is ?anti-inflammatory?, and in the present proposal we want to understand how vOX2 achieves this activity. Understanding the function of vOX2 could help understand the host?s immune response to infection and lead to new types of therapy for certain human diseases.

Normally, immune responses are beneficial, but when their control goes wrong, they can attack the body they are supposed to defend and cause inflammatory diseases such as contact dermatitis, rheumatoid arthritis, psoriasis and lung conditions like chronic obstructive pulmonary disease (COPD). The processes behind these diseases are quite well understood. We believe that vOX2, or derivatives, offers a new solution to treating these sorts of inflammatory diseases and the outcome of our proposed studies could enable the development of new types of anti-inflammatory drugs.

The data generated by our studies will be published in scientific journals, but also communicated to a more general audience through Dr. Blackbourn?s engagement in science communication with the public. Typically, this involves talking to fund-raising groups and high school students about viruses and disease, including his research.</gtr:abstractText><gtr:technicalSummary>Kaposi?s sarcoma-associated herpesvirus (KSHV) is a tumourigenic human virus that encodes an immunomodulatory protein called vOX2. The protein shares 36% identity with human cellular CD200, an inhibitor of myeloid cell activation. We hypothesise that vOX2 helps modulate the antiviral immune response, facilitating KSHV infection and dissemination. Understanding this immunomodulation is an area of active interest in DJB?s laboratory, and the subject of the present application. 

KSHV vOX2 is a glycosylated type I transmembrane protein, expressed during lytic cycle. In our studies that underpin the present proposal, we found full-length vOX2 expressed on the surface of antigen presenting cells (APCs) inhibited human leukocyte antigen (HLA)-restricted antigen-specific CD4+ and CD8+ T lymphocyte function. CD200 had the same effect. These are the first data to demonstrate inhibition of antigen-specific T cell activity by either KSHV vOX2 or CD200.

In the present proposal, we will elucidate how vOX2 and its cellular counterpart, CD200, inhibit antigen-specific T cell functions. We will use cell culture and biochemical techniques, including signaling assays, to study the function of antigen-specific T cells cocultured in the presence of appropriate APCs, engineered to express either vOX2 or CD200, and cognate antigen. T cell function will be measured principally by quantifying interferon (IFN)-gamma production, both soluble by ELISA, and intracellular by flow cytometry. We will also measure cytotoxic activity.

We hypothesise that one pathway by which vOX2 and CD200 inhibit T cell function is via ligating the human CD200 receptor (hCD200R), expressed on T cells. 

Our main objectives are: 

(1) To determine if inhibition of T cell function by vOX2 and CD200 has either HLA or antigen specificity.

(2) To determine through blocking studies, the role of hCD200R in transducing the inhibitory signal conveyed by vOX2 and CD200.

(3) To identify the intracellular pathways affected in T cells having either vOX2- or CD200-suppressed function by performing signaling studies.

(4) To identify the regions of vOX2 and CD200 responsible for conferring function with engineered mutants and recombinants.

One outcome will be further understanding of immune modulation by viruses, specifically KSHV, and also others that encode CD200 homologues. Parallel studies of cellular CD200 should provide new understanding of how T cell function is negatively regulated by this protein.

Within the remit of the MRC Infections and Immunity Research Board this application addresses interaction of pathogens with the immune system, pathogenesis and development and control of the immune system.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>403680</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>CR UK Regional Manager's meeting.  Kettering</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>F18754F9-5DE0-475A-8FDD-EA822E55AE07</gtr:id><gtr:impact>~40 minute talk on my research

Motivated CR UK employees</gtr:impact><gtr:outcomeId>E675BF2F61C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CR UK Fundraising Event to Millward Brown, Birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>F6216EC3-5CCE-4EB7-8220-98279326E2D4</gtr:id><gtr:impact>~40 minute presentation on my work

This company has selected CR UK as it's designated charity for 2009.</gtr:impact><gtr:outcomeId>CEFE63D330D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Immune modulation strategies of Kaposi's sarcoma-associated herpesvirus (KSHV) persistence</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>9E2DE3CB-C040-4923-BD22-EE7CA5CC12F8</gtr:id><gtr:impact>~40 minute lecture as Keynote Speaker, European Clinical Virology Meeting. Birmingham, UK

Unsure</gtr:impact><gtr:outcomeId>197CF7DCF77</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CR UK Legacy Event.  Birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>181AE9EE-86CC-4DAC-97B7-677917FA3EBD</gtr:id><gtr:impact>Formal presentation on my research

Members of the audience were interested in teh science, found my talk educational and were motivated to give to CR UK as judged by feedback received.</gtr:impact><gtr:outcomeId>E6F7060AB86</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>411462</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Inhibition of antigen-specific T cells by KSHV vOX2 and its cellular counterpart, CD200</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FBA15AA7-0421-4BC0-B0D3-7042373C8E3E</gtr:id><gtr:outcomeId>jgJhxbv2nuB0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>T cell clones with antigen specificity</gtr:description><gtr:id>0FC3B328-7043-41FD-85FB-EC62DB4FDC92</gtr:id><gtr:impact>Understanding of viral mechanisms of immune modulation</gtr:impact><gtr:outcomeId>663AB02C010</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>T cells</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FB85E138-64F2-4D69-9A75-55B112E6A157</gtr:id><gtr:title>Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a244f807ed1d6f0c6d6f79d10a3b867"><gtr:id>6a244f807ed1d6f0c6d6f79d10a3b867</gtr:id><gtr:otherNames>Butler LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_13489_29_22532676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E471B1CC-9EB6-4A06-A477-9666AADDFE8C</gtr:id><gtr:title>Inflammatory cell distribution in primary merkel cell carcinoma.</gtr:title><gtr:parentPublicationTitle>Cancers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a45cec11218ed1117cb969a9acc4e04"><gtr:id>7a45cec11218ed1117cb969a9acc4e04</gtr:id><gtr:otherNames>Wheat R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2072-6694</gtr:issn><gtr:outcomeId>5a35cbe4c9d765.22799307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F54BB3E4-2DD1-4DD9-9ED3-EEC4AB92B2D4</gtr:id><gtr:title>The viral interferon regulatory factors of kaposi's sarcoma-associated herpesvirus differ in their inhibition of interferon activation mediated by toll-like receptor 3.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7203f1a9027410dd3834549c2cfe7fc3"><gtr:id>7203f1a9027410dd3834549c2cfe7fc3</gtr:id><gtr:otherNames>Jacobs SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_13489_29_23115281</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECBC5F89-2F81-4349-ACBC-518DE41FC441</gtr:id><gtr:title>Infectious agents in human cancers: lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV.</gtr:title><gtr:parentPublicationTitle>Cancer letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/166a20a6643c8b0f6a06763c1896dc84"><gtr:id>166a20a6643c8b0f6a06763c1896dc84</gtr:id><gtr:otherNames>Taylor GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0304-3835</gtr:issn><gtr:outcomeId>otZhikfeaXR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>251C40EB-AFD6-4C5E-AEAD-E81989E53C00</gtr:id><gtr:title>Innate barriers to viral infection.</gtr:title><gtr:parentPublicationTitle>Future microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bf3f1f1c3ac45facc93b885f05ffa9b"><gtr:id>1bf3f1f1c3ac45facc93b885f05ffa9b</gtr:id><gtr:otherNames>Damania B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1746-0913</gtr:issn><gtr:outcomeId>pm_13489_29_22827304</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE97EEA4-030E-49F8-8FCD-DA6F1C662E40</gtr:id><gtr:title>Infection and transmission dynamics of rKSHV.219 in primary endothelial cells.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36771a91799f743bb0de0cf4570ac721"><gtr:id>36771a91799f743bb0de0cf4570ac721</gtr:id><gtr:otherNames>Jeffery HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn><gtr:outcomeId>pm_540e13be13b184d12</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6ACE52E-01B7-4AA7-8387-7070E5A7C69F</gtr:id><gtr:title>Suppression of antigen-specific T cell responses by the Kaposi's sarcoma-associated herpesvirus viral OX2 protein and its cellular orthologue, CD200.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df47dbc2e09a70b6e4b08fa97fe8bd05"><gtr:id>df47dbc2e09a70b6e4b08fa97fe8bd05</gtr:id><gtr:otherNames>Misstear K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_13489_29_22491458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66ACEAB4-F168-42C4-9D4B-41DAB607BA0D</gtr:id><gtr:title>Structural properties of a viral orthologue of cellular CD200 protein: KSHV vOX2.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaa573449a408ca1e73096e142d8b78e"><gtr:id>aaa573449a408ca1e73096e142d8b78e</gtr:id><gtr:otherNames>Amini AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>doi_55f9849849b58f28</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DDC2215-471D-4297-94C3-A06D96D8D0A0</gtr:id><gtr:title>Adenovirus E1A interacts directly with, and regulates the level of expression of, the immunoproteasome component MECL1.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eba007beeececc1565b9f0b85b2abe6f"><gtr:id>eba007beeececc1565b9f0b85b2abe6f</gtr:id><gtr:otherNames>Berhane S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>XT3a3WkN2JC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBF33DB1-76C9-45F3-99F2-C550DE0EC22F</gtr:id><gtr:title>Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor-2 inhibits type 1 interferon signalling by targeting interferon-stimulated gene factor-3.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0edf02c88c177100685290115f209db"><gtr:id>c0edf02c88c177100685290115f209db</gtr:id><gtr:otherNames>Mutocheluh M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>gdYL4KmYqW8</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800154</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>